Article
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry
19 Jan 2017
Abstract excerpt
BACKGROUND: RRx-001, a dinitroazetidine derivative, is a novel anticancer agent currently in phase II clinical trials. It mediates immunomodulatory effects either directly through polarization of tumor associated macrophages or indirectly through vascular normalization and increased T-lymphocyte infiltration. With multiple additional mechanisms of action including upregulation of oxidative stress, depletion of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
